New daily shot could replace calcium pills for rare hormone disorder

NCT ID NCT04701203

Completed Disease control Sponsor: Ascendis Pharma Bone Diseases A/S Source: ClinicalTrials.gov ↗

First seen Feb 15, 2026 · Last updated Jun 23, 2026 · Updated 18 times

Summary

This Phase 3 trial tested a daily injection of TransCon PTH, a synthetic parathyroid hormone, in 84 adults with hypoparathyroidism. The goal was to see if it could help patients maintain normal blood calcium levels while reducing their need for high-dose calcium and vitamin D supplements. Participants were randomly assigned to receive either the active drug or a placebo for 26 weeks, followed by an open-label extension where everyone received the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Ascendis Pharma Investigational Site

San Francisco, California, 94143, United States
Ascendis Pharma Investigational Site

Chicago, Illinois, 60637, United States
Ascendis Pharma Investigational Site

Rochester, Minnesota, 55905, United States
Ascendis Pharma Investigational Site

Reno, Nevada, 89511, United States
Ascendis Pharma Investigational Site

New York, New York, 10032, United States
Ascendis Pharma Investigational Site

Greenville, North Carolina, 27834, United States
Ascendis Pharma Investigational Site

Austin, Texas, 78731, United States
Ascendis Pharma Investigational Site

Fort Worth, Texas, 76132, United States
Ascendis Pharma Investigational Site

Spokane, Washington, 99204, United States
Ascendis Pharma Investigational Site

Halifax, Nova Scotia, B3H 2Y9, Canada
Ascendis Pharma Investigational Site

Oakville, Ontario, L6M 1M1, Canada
Ascendis Pharma Investigational Site

Québec, Quebec, G1V 4G2, Canada
Ascendis Pharma Investigational Site

Copenhagen, Capital Region, 2100, Denmark
Ascendis Pharma Investigational Site

Aarhus, Central Jutland, 8200, Denmark
Ascendis Pharma Investigational Site

Dresden, Saxony, 01307, Germany
Ascendis Pharma Investigational Site

Szeged, Csongrád megye, 6720, Hungary
Ascendis Pharma Investigational Site

Budapest, 1083, Hungary
Ascendis Pharma Investigational Site

Bologna, Emilia-Romagna, 40138, Italy
Ascendis Pharma Investigational Site

Rome, Lazio, 00128, Italy
Ascendis Pharma Investigational Site

Pisa, Piacenza, 56126, Italy
Ascendis Pharma Investigational Site

Oslo, 0176, Norway

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TransCon PTH (a daily injection of parathyroid hormone)

What this could lead to

If successful, this could offer a more targeted treatment for hypoparathyroidism, potentially reducing or eliminating the need for high-dose calcium and vitamin D supplements.

What could go wrong

This is a relatively small Phase 3 trial (84 participants), and results may not apply to all patients. The treatment requires daily injections and may have side effects or not work for everyone.

Conditions

The condition(s) this trial relates to.

endocrine system disorder hypoparathyroidism parathyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOCRINE SYSTEM DISEASES ENDOCRINE SYSTEM DISEASES HYPOPARATHYROIDISM PARATHYROID DISEASES